Five things for pharma marketers to know: Friday, May 19, 2017

Five things for pharma marketers to know: Friday, May 19, 2017

Keytruda gets two new FDA approvals; lawmakers aim to speed up approval of generics; Incyte uses soap opera to spread rare-disease awareness

Read the complete May 2017 digital edition

Read the complete May 2017 digital edition

Here you'll find everything from our May 2017 issue, including our Top 40 Transformers, deep dive into autoimmune drugs, and more.

Study: One-third of docs trust pharma content on HCP sites

Study: One-third of docs trust pharma content on HCP sites

In general, physicians believe that information provided by pharma companies is difficult to find and lacking in science.

Five things for pharma marketers to know: Thursday, May 18, 2017

Five things for pharma marketers to know: Thursday, May 18, 2017

Docs spend little time telling patients about cancer costs; Shire to file hereditary angioedema drug with the FDA by 2018; Philips CEO on access obstacles

Califf joins Verily, to help the firm address the needs of doctors

Califf joins Verily, to help the firm address the needs of doctors

Robert Califf stepped down from his role as FDA commissioner in January.

Five things for pharma marketers to know: Wednesday, May 17, 2017

Five things for pharma marketers to know: Wednesday, May 17, 2017

FDA requires boxed warning for J&J's Invokana; Amazon to reportedly hire GM to enter pharmacy industry; WannCry ransomware affects some health organizations

What marketers need to know about tax reform, off-label promotion, pricing

What marketers need to know about tax reform, off-label promotion, pricing

The ad-tax deduction is likely once again on the table.

Five things for pharma marketers to know: Tuesday, May 16, 2017

Five things for pharma marketers to know: Tuesday, May 16, 2017

A New York county sues drugmakers over opioid marketing; AstraZeneca files suit against GSK exec; Thermo Fisher acquires biologics firms

Califf calls for marketers to develop off-label 'code of ethics'

Califf calls for marketers to develop off-label 'code of ethics'

The former FDA commissioner said marketers need to focus on ensuring that off-label promotion is "non-misleading."

Infographic: The battle for medication adherence

Infographic: The battle for medication adherence

Drugmakers and providers alike struggle to find the best tools, words, and technologies that will improve adherence rates among patients with chronic diseases.

Five things for pharma marketers to know: Monday, May 15, 2017

Five things for pharma marketers to know: Monday, May 15, 2017

Funding for patient-assistance charities makes up 7% of operating expenses for drugmakers; Avanir ad under fire; Trump to consider Medicare rebates

Back at Dendreon, Caggiano takes on Provenge's comeback

Back at Dendreon, Caggiano takes on Provenge's comeback

Jim Caggiano had witnessed Provenge's birth during an earlier turn at Dendreon and couldn't understand what went wrong.

Mother New York fills resume gaps with 'The Pregnancy Pause'

Mother New York fills resume gaps with 'The Pregnancy Pause'

For Mother's Day, the agency gives job-hunters a way to proudly display maternity leave as a full-time job.

Five things for pharma marketers to know: Friday, May 12, 2017

Five things for pharma marketers to know: Friday, May 12, 2017

AstraZeneca's Imfinzi improves survival in lung cancer in trial; Blue Cross Blue Shield partners with Lyft; Lilly to submit migraine drug to FDA

Five things for pharma marketers to know: Thursday, May 11, 2017

Five things for pharma marketers to know: Thursday, May 11, 2017

FDA approves Merck/Lilly combo for lung cancer; new PhRMA requirements result in expulsion of 22 members; Pfizer to pay Sangamo $7 million for gene therapy programs

JUICE vet Robert Palmer joins HCB Health as chief innovation officer

JUICE vet Robert Palmer joins HCB Health as chief innovation officer

Palmer spent seven years at JUICE and was a managing partner.

INC Research to buy inVentiv Health in $4.6 billion deal

INC Research to buy inVentiv Health in $4.6 billion deal

The deal will create one of the three biggest contract research organizations in the world.

Study: One-third of new drugs report safety issues

Study: One-third of new drugs report safety issues

Drugs approved through the accelerated approval pathway, as well as psychiatric drugs, were more likely to have a safety issue following FDA approval.

Five things for pharma marketers to know: Wednesday, May 10, 2017

Five things for pharma marketers to know: Wednesday, May 10, 2017

The Senate confirms Gottlieb as FDA commissioner; Endo shares DTC plans for Xiaflex; an AstraZeneca asthma drug fails in late-stage study

CVS relies on personalization in its ExtraCare loyalty program

CVS relies on personalization in its ExtraCare loyalty program

CVS has a pharmacy text program to remind patients to refill their prescriptions and alert them when their medications are ready.

Five things for pharma marketers to know: Tuesday, May 9, 2017

Five things for pharma marketers to know: Tuesday, May 9, 2017

Sanofi ties price increases to growth rate; Regeneron to target 7,000 docs on new eczema drug Dupixent; NIH and biotech execs meet White House officials

How Truth Initiative grew an online community

How Truth Initiative grew an online community

The community manager of the smoking-prevention nonprofit reveals the key ways he drives engagement among online community members

Read the complete 2017 Game Changers digital edition

Read the complete 2017 Game Changers digital edition

Here you'll find Sara Holoubek's deep dive into how pharma is tackling some of its biggest challenges.

As sensitivities rise, the diversity officer's role expands

As sensitivities rise, the diversity officer's role expands

In the wake of high-profile brand flops, everyone from clients to creative teams seeks the counsel of experts.

J&J's Joaquin Duato: Diversity is 'essential'

J&J's Joaquin Duato: Diversity is 'essential'

Under Duato, the leadership team for Johnson & Johnson's pharma group includes six women. "We don't just talk about it," he says.

Five things for pharma marketers to know: Monday, May 8, 2017

Five things for pharma marketers to know: Monday, May 8, 2017

Pfizer to provide Ibrance for free during NICE analysis; the FDA approves new ALS drug; people turn to Twitter to tell stories about pre-existing conditions

Pharma must radically rethink its engagement with doctors

Pharma must radically rethink its engagement with doctors

Amidst the massive technological and social changes upending the societal status quo, the culture of doctors around the globe is also in flux. Technology must be humanized to advance care. McCann Health's "Truth About Doctors" study uncovers what this means for pharma marketers and how the industry can help doctors future-proof their profession.

Five things for pharma marketers to know: Friday, May 5, 2017

Five things for pharma marketers to know: Friday, May 5, 2017

CVS formulary changes lifted Tresiba sales; Novartis licenses NASH drug; FDA is building digital health unit

Bayer's Claritin campaign encourages time outdoors

Bayer's Claritin campaign encourages time outdoors

Claritin is fighting the "indoor epidemic" with its Be an Outsider campaign

Five things for pharma marketers to know: Thursday, May 4, 2017

Five things for pharma marketers to know: Thursday, May 4, 2017

Louisiana may use 1910 law to discount hep-C drugs; House bill would reduce coverage for 24 million people; drugmakers pursue pay-for-performance deals

Klick Health appoints FCB veteran as chief medical officer

Klick Health appoints FCB veteran as chief medical officer

Holly Henry, previously chief medical officer at FCB Health, will oversee medical strategy in the newly created role.

U.S. drug spend grew by 6% in 2016, the lowest rate in two years

U.S. drug spend grew by 6% in 2016, the lowest rate in two years

This is likely due to fewer product launches and lower price increases.

Gilead slowly rolls out ads for Truvada for PrEP — 4 years after approval

Gilead slowly rolls out ads for Truvada for PrEP — 4 years after approval

The drugmaker is is using Tumblr, Snapchat, and YouTube as well as gay dating apps like Grindr to promote its HIV prevention pill.

Five things for pharma marketers to know: Wednesday, May, 3, 2017

Five things for pharma marketers to know: Wednesday, May, 3, 2017

Teaching hospitals that limit detailing prescribe fewer branded drugs; new ad campaign criticizes drug pricing; Ad Age reports healthcare is fastest growing agency discipline

15 years later, a blind man sees his wedding, thanks to VR

15 years later, a blind man sees his wedding, thanks to VR

To demonstrate the power of goggles equipped with AR and VR, the assistive technology company recreated the event on Facebook Live this weekend.

Study: How brands should market to first-time parents

Study: How brands should market to first-time parents

Ketchum, which launched a parent specialty unit, surveyed 400 first-time parents to find out what brands are doing well and how they can do better.

Five things for pharma marketers to know: Tuesday, May 2, 2017

Five things for pharma marketers to know: Tuesday, May 2, 2017

Sales of Merck's Keytruda double in the first quarter; the FDA approves AstraZeneca's immunotherapy; Lilly's insulin is under investigation in two states

Admetsys wins the 2017 MM&M Startup Showdown

Admetsys wins the 2017 MM&M Startup Showdown

The artificial pancreas can provide value to the health system.

Value-based care requires innovators to challenge the status quo

Value-based care requires innovators to challenge the status quo

Execs stressed the importance of collaboration, consumer-mindedness.

Merck, Takeda execs: Is AI the new bad app?

Merck, Takeda execs: Is AI the new bad app?

One executive referred to AI as a "black box" and as the "Tower of Babel."

Pharma faces its 'oh, shit' moment

Pharma faces its 'oh, shit' moment

In his keynote address at the MM&M Transforming Healthcare conference, Dr. Gautam Gulati says the industry is being outpaced by its innovation.

Five things for pharma marketers to know: Monday, May 1, 2017

Five things for pharma marketers to know: Monday, May 1, 2017

The FDA approves osteoporosis drug; groups warn that latest healthcare bill would cut protections for pre-existing conditions; Dupixent gets PBM coverage

4 reasons why patients don't fill their prescriptions

4 reasons why patients don't fill their prescriptions

Researchers still don't know why Americans who are prescribed a prescription drug to treat a chronic condition or disease so often fail to fill those prescriptions.

Day 2 at Health Datapalooza

Day 2 at Health Datapalooza

The market for health data and technology is growing, but the industry must also address concerns about privacy, standards, and diversity.

Day 1 at Health Datapalooza

Day 1 at Health Datapalooza

HHS Secretary Tom Price calls for health IT that works for clinicians and better interoperability.

Five things for pharma marketers to know: Friday, April 28, 2017

Five things for pharma marketers to know: Friday, April 28, 2017

Express Scripts-Anthem deal highlights profitability for PBMs; Sarepta CEO steps down; study says NHS cancer drug fund was ineffective

Amgen, Sandoz argue biosimilar patent case to the Supreme Court

Amgen, Sandoz argue biosimilar patent case to the Supreme Court

Sandoz counsel argued that Amgen's position "wrongly delays the marketing of every biosimilar."

Five things for pharma marketers to know: Thursday, April 27, 2017

Five things for pharma marketers to know: Thursday, April 27, 2017

Novartis, Kaiser, and Qualcomm partner on heart-failure pilot; Novartis and GSK disclose DTC plans; cancer-treatment hype can be negative for patients

Five things for pharma marketers to know: Wednesday, April 26, 2017

Five things for pharma marketers to know: Wednesday, April 26, 2017

GSK warns Advair generic competition may affect business in 2017; Lilly plans to meet FDA about baricitinib; FDA warns companies selling 'illegal' products

Drugmakers battle for slice of Humira's billions

Drugmakers battle for slice of Humira's billions

Makers of biosimilars have targeted a few of the top-selling autoimmune drugs. Get ready for some of the highest-stakes pricing and access skirmishes in recent pharma history.

MedImmune goes after challenging lupus market

MedImmune goes after challenging lupus market

While investments in investigational lupus agents appear to be heating up, late-stage clinical failure continues to be a major hurdle to market entry.

Top 25 autoimmune brands in 2016, based on U.S. sales

Top 25 autoimmune brands in 2016, based on U.S. sales

AbbVie's Humira tops the list, according to data compiled by EvaluatePharma.

Study: Medical-marijuana laws lower prescription drug usage

Study: Medical-marijuana laws lower prescription drug usage

The research found a reduction in utilization of medications used to treat depression, nausea, and psychosis when looking at data for Medicaid beneficiaries.

Five things for pharma marketers to know: Tuesday, April 25, 2017

Five things for pharma marketers to know: Tuesday, April 25, 2017

Sanofi sues Mylan over anticompetitive practices; Anthem to drop Express Scripts; GSK chief digital officer says advertisers should focus on fewer publishers

Read the complete April 2017 digital edition

Read the complete April 2017 digital edition

Here you'll find everything you need to know from MM&M's April 2017 issue, including our DTC report, our deep dive into respiratory drugs, and more.

PerfectLens sees ROI with programmatic ad buying

PerfectLens sees ROI with programmatic ad buying

The Canadian contact lens etailer partnered with a new technology vendor to look beyond its direct click-to-conversions.

Five things for pharma marketers to know: Monday, April 24, 2017

Five things for pharma marketers to know: Monday, April 24, 2017

QuintilesIMS partners with Salesforce; the E.U. to decide on new EMA location by June; drugmakers boost lobbying dollars in Q1

Purdue Pharma hires new VP of public affairs, communications

Purdue Pharma hires new VP of public affairs, communications

Josephine Martin was previously EVP of public affairs at PhRMA.

A new tool seeks to educate docs about Parkinson's symptoms

A new tool seeks to educate docs about Parkinson's symptoms

The device could be used by physicians to better understand the severity of a patient's symptoms and elicit empathy.

Five things for pharma marketers to know: Friday, April 21, 2017

Five things for pharma marketers to know: Friday, April 21, 2017

Teva launches branded competitor to GSK's Advair; Valeant prices psoriasis drug at $3,500 per month; overseas drug importation would save money, op-ed argues

Five things for pharma marketers to know: Thursday, April 20, 2017

Five things for pharma marketers to know: Thursday, April 20, 2017

Tesaro discloses price for new drug that differs from FDA-approved dosage; uniQure discontinues Glybera; O'Reilly leaves Fox

Pharma R&D partnerships are on the rise: report

Pharma R&D partnerships are on the rise: report

This is likely due, in part, to the increasingly complex nature of new specialty drugs.

PhRMA debuts new ads in Go Boldly campaign

PhRMA debuts new ads in Go Boldly campaign

PhRMA worked with WPP Health & Wellness and Young & Rubicam on creative for the ads.

Five things for pharma marketers to know: Wednesday, April 19, 2017

Five things for pharma marketers to know: Wednesday, April 19, 2017

Valeant gave $100,000 to patient group to address affordability of its drug; Omnicom reports 3% increase in specialty group revenue; Verily to study biometric data

In Merck video, woman says a cure is the greatest invention

In Merck video, woman says a cure is the greatest invention

The drugmaker's video asks people in New York and San Francisco about their ideas for great inventions.

J&J blames lower Xarelto and Invokana sales on payer pressure

J&J blames lower Xarelto and Invokana sales on payer pressure

The drugmaker said it has been forced to provide higher rebates to PBMs and insurers for certain drugs.

Five things for pharma marketers to know: Tuesday, April 18, 2017

Five things for pharma marketers to know: Tuesday, April 18, 2017

Novartis gets Breakthrough designation for its CAR-T therapy; Duchesney continues working with Kardashian; new user-fee deal to speed up FDA approvals

Facing a competitive market, Synergy looks to stand out with unbranded emojis

Facing a competitive market, Synergy looks to stand out with unbranded emojis

The drugmaker hopes its emojis will raise awareness about treatment options for constipation.

SPONSORED: Using co-pay programs to acquire and engage patients

SPONSORED: Using co-pay programs to acquire and engage patients

Along with lower costs, effective co-pay offset programs boost patient adherence and better connect with doctors and pharmacies.

Five things for pharma marketers to know: Monday, April 17, 2017

Five things for pharma marketers to know: Monday, April 17, 2017

Kardashian West promotes Diclegis again; drugmakers are developing non-opioid painkillers; healthcare brands test Facebook Live

Some brands thought to shift online ad dollars, creating uncertainty for WebMD

Some brands thought to shift online ad dollars, creating uncertainty for WebMD

This and other changes in the market have created demand for new offerings, like mobile-friendly sites, video, and patient communities.

5 of healthcare's hardest nuts to crack

5 of healthcare's hardest nuts to crack

How are pharma, clinical, and startup execs addressing some of the biggest challenges facing their businesses today?

Regeneron uses VR to humanize retinal disease

Regeneron uses VR to humanize retinal disease

The drugmaker saw a gap in patient-physician conversation about retinal disease.

Five things for pharma marketers to know: Friday, April 14, 2017

Five things for pharma marketers to know: Friday, April 14, 2017

Lawmaker wants better enforcement of TV ads placed by lawyers; more toddlers are taking antipsychotics; Neurocrine puts off price disclosure of new drug

SPONSORED: Rebooting your approach to HUB services

SPONSORED: Rebooting your approach to HUB services

A trio of industry leaders counsels on numerous HUB strategies that will help providers vastly improve the patient experience.

Five things for pharma marketers to know: Thursday, April 13, 2017

Five things for pharma marketers to know: Thursday, April 13, 2017

Biogen licenses experimental Alzheimer's drug; Apple reportedly working on diabetes sensors; doc warns against industry payments

MM&M names winners of Young Jurists program

MM&M names winners of Young Jurists program

Meet Medela's Katie Busse, Intouch Solutions' Andrew Grojean, Heartbeat's Meghan Kate, Fingerpaint's Travis Rooke, and Havas Life Metro's Dan Sorine.

Five things for pharma marketers to know: Wednesday, April 12, 2017

Five things for pharma marketers to know: Wednesday, April 12, 2017

The FDA approves first drug to treat tardive dyskinesia; Americans use crowdfund sites to pay for prescriptions; stroke sufferers struggle with adherence

Genentech urges broader adoption of value-based payment models

Genentech urges broader adoption of value-based payment models

A study published in Health Affairs detailed an outcomes-based pilot developed by the drugmaker and Priority Health, a Michigan-based health insurer.

Off-label legal settlements do little to change prescribing patterns

Off-label legal settlements do little to change prescribing patterns

An analysis of claims data found that an off-label settlement for one Eli Lilly drug did not significantly change how often it was prescribed off-label after the settlements.

Large teaching hospitals more prone to breaches

Large teaching hospitals more prone to breaches

These facilities may be more prone to attack because there are more people at them with access to private patient data, whether to conduct medical research or educate new healthcare professionals.

Five things for pharma marketers to know: Tuesday, April 11, 2017

Five things for pharma marketers to know: Tuesday, April 11, 2017

Groups with PhRMA ties warn against drug-pricing proposals; patients learn how to be advocates; the U.K. will not cover Opdivo for head and neck cancer

Pacira, Trinity Health aim to address opioid use in surgeries

Pacira, Trinity Health aim to address opioid use in surgeries

Pacira also recently announced a partnership with Johnson & Johnson to co-promote its pain injection for certain surgeries.

Five things for pharma marketers to know: Monday, April 10, 2017

Five things for pharma marketers to know: Monday, April 10, 2017

Gilead receives approval to market Harvoni, Sovaldi to adolescents; OncoMed ends mid-stage trials for pancreatic cancer drug; researchers use facial recognition software to diagnose

Excedrin acts fast to ease Mets fan's headache

Excedrin acts fast to ease Mets fan's headache

Excedrin jumped at the chance to help relieve an angry fan's headache when he missed opening day of the New York Mets season due to train delays.

Hall of Femme of 2017

Hall of Femme of 2017

For the second year, MM&M is honoring 16 of the most-senior women in the healthcare industry.

Five things for pharma marketers to know: Friday, April 7, 2017

Five things for pharma marketers to know: Friday, April 7, 2017

The FDA rejected an outcomes update to the Januvia label; digital-health funding dropped in Q1 of 2017; the FDA approves 23andMe's genetic test

Gilead, Astellas also suspend ads on 'The O'Reilly Factor'

Gilead, Astellas also suspend ads on 'The O'Reilly Factor'

Bayer, Eli Lilly, GlaxoSmithKline, and Sanofi have suspended advertising on the show, according to news reports.

Five things for pharma marketers to know: Thursday, April 6, 2017

Five things for pharma marketers to know: Thursday, April 6, 2017

The FDA approves drugs faster than EMA; Botox goes to late-stage testing for depression; GSK recalls nearly 600,000 asthma inhalers

Analysis: Gender, racial diversity among CMOs shows little sign of progress

Analysis: Gender, racial diversity among CMOs shows little sign of progress

Several of the top-spending brands have never hired more than one female or non-white marketing boss, and some never have.

Five things for pharma marketers to know: Wednesday, April 5, 2017

Five things for pharma marketers to know: Wednesday, April 5, 2017

GSK pulls ads from "The O'Reilly Factor"; the FDA approves drug for Huntington's disease patients; lawmakers may remove pre-existing conditions requirement

How pharma marketers are using behavioral science

How pharma marketers are using behavioral science

A tool kit of pharma case studies and advice for healthcare brands in making behavioral science a foundational part of a marketing strategy.

Five things for pharma marketers to know: Tuesday, April 4, 2017

Five things for pharma marketers to know: Tuesday, April 4, 2017

Mylan allegedly increased EpiPen list price to appease PBMs; 20% of patients misdiagnosed by primary-care doctor: study; Mallinckrodt settles DEA probe

Top 40 Healthcare Transformers of 2017

Top 40 Healthcare Transformers of 2017

MM&M honors 40 upstarts and veteran innovation gurus.

Top 10 Innovation Catalysts of 2017

Top 10 Innovation Catalysts of 2017

For the first time MM&M honors a group of 10 agency execs.

Five things for pharma marketers to know: Monday, April 3, 2017

Five things for pharma marketers to know: Monday, April 3, 2017

Opdivo/Yervoy combination shows improved survival for melanoma patients in trial; global immunotherapy market likely to reach $75 billion by 2022; Mylan expands EpiPen recall

Humana navigates health insurance ups and downs

Humana navigates health insurance ups and downs

Tom Noland says protecting and enhancing Humana's reputation comes down to three things: corporate volunteerism, good media relations, and content creation.

Infographic: The physician view on patient data

Infographic: The physician view on patient data

A WebMD survey finds that patients are more engaged when they share their own health with their doctors.

Five things for pharma marketers to know: Friday, March 31, 2017

Five things for pharma marketers to know: Friday, March 31, 2017

Novartis ordered to turn over files about 80,000 speaking events; drugmakers set lower-than-expected prices at launch; funding goes to R&D of antibiotics

Cannes Lions announces pharma, health and wellness juries

Cannes Lions announces pharma, health and wellness juries

This year's festival will be held June 17 and 18.

Opinion

How to Shatter the Glass Ceiling

How Pharma Can Benefit from the Transformation of Pharmacy

Newsletters

Live at MM&M Transforming Healthcare

Pharma faces its 'oh, shit' moment

In his keynote address at the MM&M Transforming Healthcare conference, Dr. Gautam Gulati says the industry is being outpaced by its innovation.

Merck, Takeda execs: Is AI the new bad app?

One executive referred to AI as a "black box" and as the "Tower of Babel."

Value-based care requires innovators to challenge the status quo

Execs stressed the importance of collaboration, consumer-mindedness.

Admetsys wins the 2017 MM&M Startup Showdown

The artificial pancreas can provide value to the health system.

Top 40 Healthcare Transformers

MM&M honors 40 upstarts and veteran innovation gurus.

Top 10 Innovation Catalysts

For the first time MM&M honors a group of 10 agency execs.